Cancer biologist with a primary interest in Target ID, Validation & Drug Discovery• Currently the biology and in vivo pharmacology lead of a multidisciplinary oncology program in pre-clinical drug discovery stage.• Previously: designed and lead the biology efforts of a multidisciplinary project in early discovery and hit finding stage. Also, lead biology and in vivo pharmacology efforts of a project at clinical development stage: Designed and executed in vitro and in vivo studies to demonstrate the mechanism of action and efficacy of a clinical stage drug in new indications.• 4 years of expertise in Target ID, Validation efforts in apoptosis pathway, E3-ubiquitin ligase, targeted protein degradation, functional genomic tools, and screening techniques (with Dr. William Sellers at Broad Institute).• 8 years of experience in signaling, genetic, and epigenetic regulation of cancer initiation, evolution, metastasis and drug resistance (with Dr Raffaella Sordella at CSHL).• Consistent track record of scientific excellence, as demonstrated by publications.• A thoughtful mentor helping junior scientists and colleagues develop their projects and careers.• Experience with managing multiple industry collaborations.